A Phase 2 Study of Zanubrutinib in Previously Treated B-Cell Malignancies Intolerant to Ibrutinib and/or Acalabrutinib: Preliminary Results for Patients With CLL/SLL


Key opinion leader Mazyar Shadman, MD, MPH, reviews data from a clinical trial studying zanubrutinib in the context of ibrutinib- and/or acalabrutinib-intolerant CLL/SLL.

Related Videos
Alexey Danilov, MD, PhD, an expert on mantle cell lymphoma
John N. Allan, MD
Nicole Lamanna, MD
Mark A. Socinski, MD, an expert on lung cancer, presenting slides
Hope Rugo, MD, an expert on breast cancer, presenting slides
Expert on NSCLC
Brian Slomovitz, MD, an expert on cervical cancer, presenting data